Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: NeuroRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 21, 2020
Details:
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: BioNTech SE
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 17, 2020
Details:
Facility will become one of the largest mRNA manufacturing sites in Europe and the third site in the BioNTech manufacturing network in Germany expected to produce BNT162 for global supply.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
Data Monitoring Committee determined that so far RLF-100 has generated no drug-related Serious Adverse Events or other safety concerns that would mandate stopping. The study is to continue until the next scheduled data review in four weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
Details:
NeuroRx has filed an investigational protocol with the U.S. FDA under CTAP to conduct a Phase 2/3 trial of inhaled RLF-100 as a treatment for patients with non-acute lung injury caused by COVID-19.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
